Open Nav

Embera NeuroTherapeutics, Inc.

  • Bob Linke, Embera NeuroTherapeutics, Inc.

Identify investors to complete Series B financing

  • Date:Wednesday, October 17
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Embera is a clinical stage pharma company focused on smoking cessation, cocaine use disorder (CUD) and other significant stress mediated diseases. Embera is developing a novel, patented drug combination (EMB-001) targeting the stress response system and specific brain functions that drive craving and relapse related to these addictions. A pilot clinical study in cocaine-dependent human subjects has been completed, showing the potential for EMB-001 to be effective in this disorder. Embera’s lead development programs are CUD and smoking cessation. Embera also completed an animal study in nicotine addiction in which EMB-001 was shown to be significantly more effective than Chantix®, Pfizer’s $998M smoking cessation product. Embera has completed its Phase 1 clinical program and is advancing CUD and smoking cessation products into Phase 2 clinical development. The EMB-001 CUD Phase 2 development program is supported by an $11.1M NIH grant.
  • Company
  • Company HQ City:Sudbury
  • Company HQ Country:United States
  • Company HQ State:Massachusetts       
  • CEO/Top Company Official:Bob Linke
  • Year Founded:2007
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :EMB-001
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:EMB-001 results have generated significant interest from the pharma industry. Embera has on-going discussions with 24 companies worldwide seeking to enter into a transaction with Embera upon completion of Phase 2 clinical studies funded by the Series B financing and NIH grant. Embera anticipates one of two exits for investors post-Phase 2, a transaction with one of the above pharma companies which the Series B funds or via an IPO, as we complete Phase 2.
  • Previous and Current Investors:Themelios Ventures, Louisiana Ventures, Louisiana Fund I, Family Office, Strategic Investor
  • Size of Last Investment Round:$5.3M
  • Total Amount Raised to Date, In All Rounds:$15M
Bob Linke
Embera NeuroTherapeutics, Inc.